glp-1 meds corona Researchers are launching a new study to investigate whether drugs, already approved for type 2 diabetes and obesity, could help treat long COVID symptoms. The medications are currently being studied for Covering GLP-1 Drugs: Employers' Top

Dulaglutide (Trulicity) Exenatide (Byetta, Bydureon) Liraglutide (Victoza, Saxenda) Lixisenatide (Adlyxin) Semaglutide (Ozempic, Rybelsus, Wegovy) Tirzepatide (Mounjaro, Zepbound)

However, clinical data comparing UTI rates between formulations is not yet available, and the fundamental pharmacological mechanism remains the same regardless of how the medication enters the body

307 Currently, targeted CXCR1/2 antagonists, such as Reparixin, have not been evaluated in clinical studies of AP, although they have shown promising anti-inflammatory effects in transplant-related settings

[DOI] [PMC free article] [PubMed] [Google Scholar] 46.Sohn M.B., Gao B., Kendrick C., Srivastava A., Isakova T., Gassman J.J., Fried L.F., Wolf M., Cheung A.K., Raphael K.L., et al

Organisations need to recognise that manufacturing capacity must be secured earlier in the development lifecycle

One meta-analysis and systemic review of 26 trials published in April 2025 in JAMA Neurology suggested that they could help lower dementia risk